Dr Thais Reif De Paula, MD | |
100 E Lancaster Ave, Mob South 422, Wynnewood, PA 19096-3450 | |
(484) 476-1619 | |
(484) 476-3354 |
Full Name | Dr Thais Reif De Paula |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 100 E Lancaster Ave, Wynnewood, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043070121 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | MT230581 (Pennsylvania) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Thais Reif De Paula, MD 100 E Lancaster Ave, Mob South 422, Wynnewood, PA 19096-3450 Ph: (484) 476-1619 | Dr Thais Reif De Paula, MD 100 E Lancaster Ave, Mob South 422, Wynnewood, PA 19096-3450 Ph: (484) 476-1619 |
News Archive
Few internists who care for cancer survivors address issues of sexual dysfunction with their patients, according to a study led by Massachusetts General Hospital (MGH) researchers. In their article appearing in a November 2009 cancer survivor supplement to the Journal of General Internal Medicine, now available online, the investigators report that more than half the internists responding to a survey indicated they rarely or never discussed sexual problems with their patients who had survived cancer.
Today, Smart Holograms, a UK-Based Technology Company, announced the commercial availability of its new Verif-EYE™ bio-optical, interactive visual sensor that allows consumers to ‘self validate' their purchases prior to consumption or use to ensure the product is genuine and tamper-free.
DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.
Dr. Philippe De Wals of Universit' Laval's Department of Social and Preventive Medicine today publishes a study clearly indicating that the addition of folic acid to flours has led to a 46% drop in the incidence of congenital neural tube deformation (mainly anencephaly and spina bifida) in Canada. Such deformations either result in the child's death or in major health problems, including physical and learning disabilities.
› Verified 7 days ago